The estimated Net Worth of John W. Higuchi is at least $2.73 Milión dollars as of 31 December 2020. Mr. Higuchi owns over 6,700 units of Lipocine Inc stock worth over $2,718,708 and over the last 9 years he sold LPCN stock worth over $9,045. In addition, he makes $0 as Non-Executive Director at Lipocine Inc.
Sign up
Mr. Higuchi LPCN stock SEC Form 4 insiders trading
John has made over 6 trades of the Lipocine Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 6,700 units of LPCN stock worth $9,045 on 31 December 2020.
The largest trade he's ever made was buying 220,000 units of Lipocine Inc stock on 17 March 2020 worth over $70,400. On average, John trades about 14,218 units every 113 days since 2015. As of 31 December 2020 he still owns at least 693,548 units of Lipocine Inc stock.
You can see the complete history of Mr. Higuchi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Higuchi biography
John W. Higuchi is a Non-Executive Director of Lipocine Inc. Since 2003, Mr. Higuchi has served as President and Chief Executive Officer of Aciont Inc., an ocular therapeutics company. From 1997 to 2003, Mr. Higuchi served as our Vice President of Business Development and Corporate Treasurer. Mr. Higuchi also has worked for the American Chemical Society. Mr. Higuchi received a B.S. in Chemistry from Hope College and an M.B.A. and Master of Science in Information Systems from The George Washington University.
How old is John Higuchi?
John Higuchi is 47, he's been the Non-Executive Director of Lipocine Inc since 2013. There are 12 older and no younger executives at Lipocine Inc. The oldest executive at Lipocine Inc is Dr. Mahesh V. Patel Ph.D., 64, who is the Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO.
What's John Higuchi's mailing address?
John's mailing address filed with the SEC is C/O 675 ARAPEEN DR, SUITE 202, SALT LAKE CITY, UT, 84108.
Insiders trading at Lipocine Inc
Over the last 11 years, insiders at Lipocine Inc have traded over $9,045 worth of Lipocine Inc stock and bought 890,945 units worth $696,169 . The most active insiders traders include Mahesh V. Patel, John W. Higuchi a Morgan R Brown. On average, Lipocine Inc executives and independent directors trade stock every 72 days with the average trade being worth of $148,846. The most recent stock trade was executed by Mahesh V. Patel on 25 May 2023, trading 8,706 units of LPCN stock currently worth $43,791.
What does Lipocine Inc do?
lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.
What does Lipocine Inc's logo look like?
Complete history of Mr. Higuchi stock trades at Lipocine Inc
Lipocine Inc executives and stock owners
Lipocine Inc executives and other stock owners filed with the SEC include:
-
Mahesh Patel,
Chairman of the Board, President, Chief Executive Officer -
Dr. Mahesh V. Patel Ph.D.,
Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO -
Dr. Mahesh V. Patel,
Co-Founder, Chairman, Pres & CEO -
Morgan R. Brown CPA, CPA, M.B.A., MBA,
Corp. Sec. -
Morgan R. Brown CPA, M.B.A., CPA, MBA,
Exec. VP, CFO, Principal Accounting Officer & Corp. Sec. -
Morgan Brown,
Chief Financial Officer, Executive Vice President -
Nachiappan Chidambaram Ph.D.,
VP of Product Devel. -
John Higuchi,
Non-Executive Director -
Richard Ono,
Director -
Jeffrey Fink,
Director -
Stephen Hill,
Lead Independent Director -
Krista Fogarty,
Principal Accounting Officer & Corp. Controller -
Dr. Anthony DelConte M.D., M. D.,
Chief Medical Director -
Logan Morse,
VP of Sales, Marketing & Operations -
Jyrki Mattila,
Chief Business Officer -
Gregory Brooks Bass,
EVP and Chief Commercial Offic -
Srinivasan Venkateshwaran,
CTO and VP RandD -
Gerald T Simmons,
VP Corp Business Development -
Robert K. Merrell,
VP Finance -
Jill M. Jene,
Director -
Spyros Papapetropoulos,
Director -
Krista Fogarty,
Principal Accounting Officer -
George Nomikos,
Chief Medical Officer